AZD2461: Novel PARP Inhibitor for Breast Cancer & DNA Repair Modulation

Executive Summary: AZD2461 is a next-generation poly (ADP-ribose) polymerase (PARP) inhibitor with an IC₅₀ of 5 nM, targeting PARP-1 and disrupting DNA repair in breast cancer cell lines (APExBIO). It induces cell cycle arrest at the G2 phase and reduces cell viability in MCF-7 and SKBR-3 cells in a time- and concentration-dependent manner. In vivo, AZD2461 prolongs relapse-free survival in BRCA1-mutated tumor models and is well tolerated over long-term administration. The compound displays low affinity for P-glycoprotein, suggesting an ability to overcome common drug resistance mechanisms (Schwartz 2022). AZD2461 is recommended for use at 5–50 μM in cell culture, soluble in DMSO and ethanol but not water, and is provided by APExBIO as product A4164.

Biological Rationale

Poly (ADP-ribose) polymerases are enzymes essential for cellular DNA repair processes, especially in response to single-strand DNA breaks (Schwartz 2022). Cancer cells, particularly those harboring BRCA1 or BRCA2 mutations, are highly dependent on PARP-mediated repair pathways for survival. Inhibition of PARP activity can lead to accumulation of DNA damage, cell cycle arrest, and apoptosis, making PARP inhibitors like AZD2461 valuable for targeted cancer therapy (see related review). AZD2461 was developed to address limitations of earlier PARP inhibitors, including resistance due to drug efflux via P-glycoprotein.

Mechanism of Action of AZD2461

AZD2461 is a small-molecule inhibitor of PARP-1, with a molecular weight of 395.43 and the formula C₂₂H₂₂FN₃O₃ (APExBIO). It binds to the catalytic site of PARP-1, blocking its enzymatic activity and preventing poly-ADP-ribosylation of target proteins. This inhibition disrupts the repair of single-strand DNA breaks, leading to double-strand breaks during replication, which are lethal to cells deficient in homologous recombination repair (e.g., BRCA1-mutated). Mechanistically, AZD2461 causes cell cycle arrest at the G2 phase and reduces the proportion of cells in S phase, as confirmed in human breast cancer lines MCF-7 and SKBR-3 following 48–72 h incubation at 5–50 μM (Schwartz 2022, Fig. 3.4). In vivo, AZD2461 inhibits tumor PARP activity within hours, with PAR levels returning to baseline by 24 h post-dose.

Evidence & Benchmarks

• AZD2461 exhibits a potent IC₅₀ of 5 nM for PARP-1 enzymatic inhibition in biochemical assays (APExBIO).
• Reduces viable MCF-7 and SKBR-3 breast cancer cell numbers in a concentration- and time-dependent manner following 48–72 h treatment at 5–50 μM (Schwartz 2022).
• Induces cell cycle arrest with increased G2-phase and decreased S-phase populations in vitro (Schwartz 2022, Table 3.1).
• Inhibits PARP activity in BRCA1-mutant tumor-bearing mice for several hours post-administration; PAR levels normalize within 24 h (Schwartz 2022).
• Shows lower affinity for P-glycoprotein compared to olaparib, supporting use in Pgp-mediated drug-resistant models (APExBIO).
• Prolongs median relapse-free survival in murine tumor models with chronic administration, demonstrating tolerability (Schwartz 2022, Ch. 4).

This article extends the mechanistic analyses presented in 'AZD2461 and the Next Era of PARP Inhibition: Mechanistic ...' by providing updated, product-specific workflow and benchmarking data, and it clarifies translational parameters for integrating AZD2461 in current breast cancer research models.

Applications, Limits & Misconceptions

AZD2461 is optimized for use in cancer cell lines deficient in homologous recombination repair, especially BRCA1/2-mutated breast cancer and preclinical tumor models. Its low Pgp affinity facilitates experiments on drug resistance reversal. It is suitable for in vitro cell viability, cell cycle, and apoptosis assays, as well as in vivo tumor suppression and relapse-free survival studies. For advanced workflows, AZD2461 enables precision modulation of the DNA repair pathway, making it central to studies of synthetic lethality and systems-level PARP signaling (see strategic roadmap).

Common Pitfalls or Misconceptions

• AZD2461 is insoluble in water; DMSO or ethanol (with ultrasonic assistance) is required for stock solution preparation (APExBIO).
• Not all cancer types are equally sensitive; efficacy is highest in homologous recombination-deficient lines (not universal to all tumors) (Schwartz 2022).
• Long-term stock solutions are unstable; fresh preparations are recommended for each experiment (APExBIO).
• AZD2461 does not reverse resistance mediated by non-Pgp mechanisms (e.g., restoration of homologous recombination) (see advanced troubleshooting).
• Results from in vitro models may not fully predict clinical efficacy in human patients; translational studies are needed (Schwartz 2022).

Workflow Integration & Parameters

For experimental use, AZD2461 (A4164) should be stored at -20°C and prepared in DMSO (≥16.35 mg/mL) or ethanol (≥45.2 mg/mL, ultrasonic-assisted). Typical working concentrations are 5–50 μM in cell culture; incubation periods range from 48 to 72 hours. For in vivo tumor models, dosing schedules should be adapted based on pharmacokinetic and relapse-free survival endpoints. Key readouts include PARP activity assays, cell cycle distribution (flow cytometry), and cell viability (relative and fractional) (Schwartz 2022). For detailed guidance on troubleshooting and optimizing experimental protocols, see 'AZD2461: Novel PARP Inhibitor Advancing Breast Cancer Res...', which provides extended troubleshooting and strategic insights for maximizing translational impact.

Conclusion & Outlook

AZD2461, available from APExBIO, is a robust tool for advancing research in breast cancer, DNA repair, and drug resistance. Its potent and selective PARP-1 inhibition, low Pgp affinity, and favorable tolerability profile make it well-suited for both in vitro and in vivo models. As research evolves, AZD2461 will continue to support new strategies for synthetic lethality and relapse-free survival in cancer models. For a systems-level perspective on DNA repair pathway modulation and the future of PARP inhibitors, readers can consult this deep-dive review, which AZD2461 data now extends with updated benchmarks and workflow recommendations.